Biomedical Potential of mTOR Modulation by Nanoparticles.
Identifieur interne : 000B36 ( Main/Exploration ); précédent : 000B35; suivant : 000B37Biomedical Potential of mTOR Modulation by Nanoparticles.
Auteurs : Laura Hulea [Canada] ; Zoran Markovic [Slovaquie] ; Ivan Topisirovic [Canada] ; Thomas Simmet [Allemagne] ; Vladimir Trajkovic [Serbie]Source :
- Trends in biotechnology [ 1879-3096 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- effets des médicaments et des substances chimiques : Transduction du signal.
- Animaux, Humains, Nanomédecine, Nanoparticules, Souris, Sérine-thréonine kinases TOR.
English descriptors
- KwdEn :
- MESH :
- chemical : TOR Serine-Threonine Kinases.
- drug effects : Signal Transduction.
- Animals, Humans, Mice, Nanomedicine, Nanoparticles.
Abstract
Modulation of the mammalian target of rapamycin (mTOR), the principal regulator of cellular homeostasis, underlies the biological effects of engineered nanoparticles, including regulation of cell death/survival and metabolic responses. Understanding the mechanisms and biological actions of nanoparticle-mediated mTOR modulation may help in developing safe and efficient nanotherapeutics to fight human disease.
DOI: 10.1016/j.tibtech.2016.01.005
PubMed: 26900005
Affiliations:
- Allemagne, Canada, Serbie, Slovaquie
- Bade-Wurtemberg, District de Tübingen, Québec
- Montréal, Ulm
- Université McGill
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomedical Potential of mTOR Modulation by Nanoparticles.</title><author><name sortKey="Hulea, Laura" sort="Hulea, Laura" uniqKey="Hulea L" first="Laura" last="Hulea">Laura Hulea</name><affiliation wicri:level="4"><nlm:affiliation>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6, Canada. Electronic address: laura.hulea@mail.mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Markovic, Zoran" sort="Markovic, Zoran" uniqKey="Markovic Z" first="Zoran" last="Markovic">Zoran Markovic</name><affiliation wicri:level="1"><nlm:affiliation>Vinca Institute of Nuclear Sciences, University of Belgrade, PO Box 522, 11000 Belgrade, Serbia; Polymer Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, Slovakia.</nlm:affiliation><country xml:lang="fr">Slovaquie</country><wicri:regionArea>Vinca Institute of Nuclear Sciences, University of Belgrade, PO Box 522, 11000 Belgrade, Serbia; Polymer Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava</wicri:regionArea><wicri:noRegion>Bratislava</wicri:noRegion></affiliation></author><author><name sortKey="Topisirovic, Ivan" sort="Topisirovic, Ivan" uniqKey="Topisirovic I" first="Ivan" last="Topisirovic">Ivan Topisirovic</name><affiliation wicri:level="4"><nlm:affiliation>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Simmet, Thomas" sort="Simmet, Thomas" uniqKey="Simmet T" first="Thomas" last="Simmet">Thomas Simmet</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Helmholtzstrasse 20, 89081 Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Helmholtzstrasse 20, 89081 Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Trajkovic, Vladimir" sort="Trajkovic, Vladimir" uniqKey="Trajkovic V" first="Vladimir" last="Trajkovic">Vladimir Trajkovic</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Dr. Subotica 1, 11000 Belgrade, Serbia. Electronic address: vtrajkovic@med.bg.ac.rs.</nlm:affiliation><country xml:lang="fr">Serbie</country><wicri:regionArea>Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Dr. Subotica 1, 11000 Belgrade</wicri:regionArea><wicri:noRegion>11000 Belgrade</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26900005</idno><idno type="pmid">26900005</idno><idno type="doi">10.1016/j.tibtech.2016.01.005</idno><idno type="wicri:Area/Main/Corpus">000B02</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B02</idno><idno type="wicri:Area/Main/Curation">000B02</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B02</idno><idno type="wicri:Area/Main/Exploration">000B02</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Biomedical Potential of mTOR Modulation by Nanoparticles.</title><author><name sortKey="Hulea, Laura" sort="Hulea, Laura" uniqKey="Hulea L" first="Laura" last="Hulea">Laura Hulea</name><affiliation wicri:level="4"><nlm:affiliation>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6, Canada. Electronic address: laura.hulea@mail.mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Markovic, Zoran" sort="Markovic, Zoran" uniqKey="Markovic Z" first="Zoran" last="Markovic">Zoran Markovic</name><affiliation wicri:level="1"><nlm:affiliation>Vinca Institute of Nuclear Sciences, University of Belgrade, PO Box 522, 11000 Belgrade, Serbia; Polymer Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, Slovakia.</nlm:affiliation><country xml:lang="fr">Slovaquie</country><wicri:regionArea>Vinca Institute of Nuclear Sciences, University of Belgrade, PO Box 522, 11000 Belgrade, Serbia; Polymer Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava</wicri:regionArea><wicri:noRegion>Bratislava</wicri:noRegion></affiliation></author><author><name sortKey="Topisirovic, Ivan" sort="Topisirovic, Ivan" uniqKey="Topisirovic I" first="Ivan" last="Topisirovic">Ivan Topisirovic</name><affiliation wicri:level="4"><nlm:affiliation>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Simmet, Thomas" sort="Simmet, Thomas" uniqKey="Simmet T" first="Thomas" last="Simmet">Thomas Simmet</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Helmholtzstrasse 20, 89081 Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Helmholtzstrasse 20, 89081 Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Trajkovic, Vladimir" sort="Trajkovic, Vladimir" uniqKey="Trajkovic V" first="Vladimir" last="Trajkovic">Vladimir Trajkovic</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Dr. Subotica 1, 11000 Belgrade, Serbia. Electronic address: vtrajkovic@med.bg.ac.rs.</nlm:affiliation><country xml:lang="fr">Serbie</country><wicri:regionArea>Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Dr. Subotica 1, 11000 Belgrade</wicri:regionArea><wicri:noRegion>11000 Belgrade</wicri:noRegion></affiliation></author></analytic><series><title level="j">Trends in biotechnology</title><idno type="eISSN">1879-3096</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Humans (MeSH)</term><term>Mice (MeSH)</term><term>Nanomedicine (MeSH)</term><term>Nanoparticles (MeSH)</term><term>Signal Transduction (drug effects)</term><term>TOR Serine-Threonine Kinases (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Humains (MeSH)</term><term>Nanomédecine (MeSH)</term><term>Nanoparticules (MeSH)</term><term>Souris (MeSH)</term><term>Sérine-thréonine kinases TOR (MeSH)</term><term>Transduction du signal (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Transduction du signal</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Mice</term><term>Nanomedicine</term><term>Nanoparticles</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Nanomédecine</term><term>Nanoparticules</term><term>Souris</term><term>Sérine-thréonine kinases TOR</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Modulation of the mammalian target of rapamycin (mTOR), the principal regulator of cellular homeostasis, underlies the biological effects of engineered nanoparticles, including regulation of cell death/survival and metabolic responses. Understanding the mechanisms and biological actions of nanoparticle-mediated mTOR modulation may help in developing safe and efficient nanotherapeutics to fight human disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26900005</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3096</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>05</Month></PubDate></JournalIssue><Title>Trends in biotechnology</Title><ISOAbbreviation>Trends Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Biomedical Potential of mTOR Modulation by Nanoparticles.</ArticleTitle><Pagination><MedlinePgn>349-353</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0167-7799(16)00018-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tibtech.2016.01.005</ELocationID><Abstract><AbstractText>Modulation of the mammalian target of rapamycin (mTOR), the principal regulator of cellular homeostasis, underlies the biological effects of engineered nanoparticles, including regulation of cell death/survival and metabolic responses. Understanding the mechanisms and biological actions of nanoparticle-mediated mTOR modulation may help in developing safe and efficient nanotherapeutics to fight human disease.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hulea</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6, Canada. Electronic address: laura.hulea@mail.mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markovic</LastName><ForeName>Zoran</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Vinca Institute of Nuclear Sciences, University of Belgrade, PO Box 522, 11000 Belgrade, Serbia; Polymer Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topisirovic</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Lady Davis Institute, SMBD Jewish General Hospital and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec H2W 1S6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmet</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Helmholtzstrasse 20, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trajkovic</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Dr. Subotica 1, 11000 Belgrade, Serbia. Electronic address: vtrajkovic@med.bg.ac.rs.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Biotechnol</MedlineTA><NlmUniqueID>8310903</NlmUniqueID><ISSNLinking>0167-7799</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Trends Biotechnol. 2016 Nov;34(11):850-852</RefSource><PMID Version="1">27600001</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050997" MajorTopicYN="Y">Nanomedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="Y">TOR Serine-Threonine Kinases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">autophagy</Keyword><Keyword MajorTopicYN="Y">cancer</Keyword><Keyword MajorTopicYN="Y">cell death</Keyword><Keyword MajorTopicYN="Y">mTOR</Keyword><Keyword MajorTopicYN="Y">nanoparticles</Keyword><Keyword MajorTopicYN="Y">oxidative stress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26900005</ArticleId><ArticleId IdType="pii">S0167-7799(16)00018-4</ArticleId><ArticleId IdType="doi">10.1016/j.tibtech.2016.01.005</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>Serbie</li><li>Slovaquie</li></country><region><li>Bade-Wurtemberg</li><li>District de Tübingen</li><li>Québec</li></region><settlement><li>Montréal</li><li>Ulm</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><country name="Canada"><region name="Québec"><name sortKey="Hulea, Laura" sort="Hulea, Laura" uniqKey="Hulea L" first="Laura" last="Hulea">Laura Hulea</name></region><name sortKey="Topisirovic, Ivan" sort="Topisirovic, Ivan" uniqKey="Topisirovic I" first="Ivan" last="Topisirovic">Ivan Topisirovic</name></country><country name="Slovaquie"><noRegion><name sortKey="Markovic, Zoran" sort="Markovic, Zoran" uniqKey="Markovic Z" first="Zoran" last="Markovic">Zoran Markovic</name></noRegion></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Simmet, Thomas" sort="Simmet, Thomas" uniqKey="Simmet T" first="Thomas" last="Simmet">Thomas Simmet</name></region></country><country name="Serbie"><noRegion><name sortKey="Trajkovic, Vladimir" sort="Trajkovic, Vladimir" uniqKey="Trajkovic V" first="Vladimir" last="Trajkovic">Vladimir Trajkovic</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26900005
|texte= Biomedical Potential of mTOR Modulation by Nanoparticles.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26900005" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |